サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534102

炭疽菌治療薬の世界市場

Anthrax Therapeutics

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
炭疽菌治療薬の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

炭疽菌治療薬の世界市場は2030年までに6億7,160万米ドルに達する見込み

2023年に4億2,120万米ドルと推定される炭疽菌治療薬の世界市場は、2023年から2030年にかけてCAGR 6.9%で成長し、2030年には6億7,160万米ドルに達すると予測されます。本レポートで分析したセグメントの一つである抗生物質は、CAGR7.1%を記録し、分析期間終了時には4億2,050万米ドルに達すると予測されます。免疫グロブリンセグメントの成長率は、分析期間中CAGR 6.7％と推定されます。

米国市場は推定1億1,070万米ドル、中国はCAGR6.7%で成長予測

米国の炭疽菌治療薬市場は、2023年に1億1,070万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億720万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.7%です。その他の注目すべき地域市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.4％と5.8％と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の炭疽菌治療薬市場- 主要動向と促進要因のまとめ

炭疽菌（Bacillus anthracis）によって引き起こされる炭疽は、動物と人間の両方に感染する深刻な感染症です。皮膚型、吸入型、消化器型の3つの型があり、それぞれ重症度が異なります。歴史的に、炭疽菌は生物兵器として使用される可能性があり、重要な懸念事項でした。その結果、効果的な炭疽菌治療薬の開発が公衆衛生と生物防衛の両面で優先されてきました。炭疽菌の治療には、シプロフロキサシン、ドキシサイクリン、ペニシリンなどの抗生物質が用いられるが、これらは感染初期に投与するのが最も効果的です。抗生物質に加え、ラキシバクマブや炭疽免疫グロブリンのような抗毒素薬も開発され、炭疽菌が産生する毒素を中和します。

炭疽菌治療薬の分野における進歩は、継続的な調査と病態生理学の深い理解によって推進されてきました。最近の動向としては、炭疽毒素をより効果的に中和する標的を絞った新しい抗毒素やモノクローナル抗体の開発が挙げられます。さらに、より少ない投与量で長期的な免疫を獲得することを目的とした次世代ワクチンの開発も大きく進展しています。また、ナノテクノロジーを利用したドラッグデリバリーの研究も進められており、既存の治療法の有効性を高め、副作用を軽減する可能性があります。こうした技術的進歩は、特に迅速かつ効果的な対応メカニズムが不可欠なバイオテロリズムを含むシナリオにおいては極めて重要です。

炭疽菌治療薬市場の成長は、バイオテロの脅威に対する意識の高まり、バイオディフェンス構想に対する政府資金の増加、医療技術の進歩など、いくつかの要因によってもたらされます。製薬会社による研究開発への継続的な投資は、革新的な治療法やワクチンのイントロダクション拍車をかけています。さらに、バイオテロの脅威に対応した新規治療薬に対する規制当局の支援と承認の迅速化が、市場の成長を加速させています。政府や保健機関による炭疽菌治療薬の備蓄需要も、潜在的なアウトブレイクへの備えを確実にする重要な推進力となっています。さらに、官民の協力関係の高まりは、より効果的で利用しやすい炭疽菌治療の開発を促進しています。このような動向が続く中、炭疽菌治療薬市場は、継続的な技術革新と公衆衛生の安全性向上を目指した新製品の強力なパイプラインに支えられ、持続的な成長を遂げようとしています。

調査対象企業の例（全86件）

  • AbVacc, Inc.
  • Aphios Corporation
  • BlueWillow Biologics
  • Crestone
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • GC Biopharma corp.
  • Hawaii Biotech, Inc.
  • iNtRON Biotechnology
  • Lupin Ltd.
  • Paratek Pharmaceuticals
  • Pfizer Inc.
  • Porton Biopharma Limited
  • Soligenix
  • VLP Biotech;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP26861

Global Anthrax Therapeutics Market to Reach US$671.6 Million by 2030

The global market for Anthrax Therapeutics estimated at US$421.2 Million in the year 2023, is expected to reach US$671.6 Million by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$420.5 Million by the end of the analysis period. Growth in the Immunoglobulins segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$110.7 Million While China is Forecast to Grow at 6.7% CAGR

The Anthrax Therapeutics market in the U.S. is estimated at US$110.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$107.2 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Anthrax Therapeutics Market - Key Trends and Drivers Summarized

Anthrax, caused by the bacterium Bacillus anthracis, is a serious infectious disease that affects both animals and humans. It can manifest in three forms: cutaneous, inhalational, and gastrointestinal, each varying in severity. Historically, anthrax has been a significant concern due to its potential use as a biological weapon. As a result, the development of effective anthrax therapeutics has been a priority in both public health and biodefense. The mainstays of anthrax treatment include antibiotics such as ciprofloxacin, doxycycline, and penicillin, which are most effective when administered early in the course of infection. In addition to antibiotics, antitoxins like raxibacumab and anthrax immune globulin have been developed to neutralize the toxins produced by the bacteria, which can cause severe systemic effects.

Advancements in the field of anthrax therapeutics have been driven by ongoing research and a deeper understanding of the disease's pathophysiology. Recent innovations include the development of new antitoxins and monoclonal antibodies that offer targeted approaches to neutralize the anthrax toxins more effectively. Moreover, there has been significant progress in the creation of next-generation vaccines aimed at providing long-term immunity with fewer doses. Research is also exploring the use of nanotechnology for the targeted delivery of drugs, which could enhance the efficacy and reduce the side effects of existing treatments. These technological advancements are crucial, especially in scenarios involving bioterrorism, where rapid and effective response mechanisms are essential.

The growth in the anthrax therapeutics market is driven by several factors, including heightened awareness of bioterrorism threats, increased government funding for biodefense initiatives, and advancements in medical technology. The ongoing investment in research and development by pharmaceutical companies is spurring the introduction of innovative treatments and vaccines. Additionally, regulatory support and the fast-tracking of approvals for new therapeutics in response to bioterrorism threats are accelerating market growth. The demand for stockpiling of anthrax therapeutics by governments and health organizations is also a significant driver, ensuring preparedness for potential outbreaks. Furthermore, increasing collaborations between public and private sectors are fostering the development of more effective and accessible anthrax treatments. As these trends continue, the anthrax therapeutics market is poised for sustained growth, bolstered by continuous innovations and a robust pipeline of new products aimed at enhancing public health security.

Select Competitors (Total 86 Featured) -

  • AbVacc, Inc.
  • Aphios Corporation
  • BlueWillow Biologics
  • Crestone
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • GC Biopharma corp.
  • Hawaii Biotech, Inc.
  • iNtRON Biotechnology
  • Lupin Ltd.
  • Paratek Pharmaceuticals
  • Pfizer Inc.
  • Porton Biopharma Limited
  • Soligenix
  • VLP Biotech;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Anthrax Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Heightened Awareness of Bioterrorism Threats Spurs Growth in Anthrax Therapeutics Market
    • Increased Government Funding for Biodefense Initiatives Expands Market Opportunity
    • Advancements in Medical Technology Propel Innovation in Anthrax Treatments
    • Demand for Stockpiling by Governments and Health Organizations Generates Steady Market Demand
    • Innovations in Antitoxins and Monoclonal Antibodies Propel Market Growth
    • Development of Next-Generation Vaccines Expands Addressable Market Opportunity
    • Use of Nanotechnology in Drug Delivery Enhances Efficacy and Reduces Side Effects
    • Economic and Geopolitical Factors Drive Investment in Biodefense Preparedness
    • Evolution of Pathogen Detection Technologies Supports Early Intervention and Treatment
    • Increased Focus on Long-Term Immunity Solutions Drives Vaccine Innovation
    • Advances in Genomic Research Generate Opportunities for Personalized Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anthrax Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anthrax Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Anthrax Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Anthrax Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Anthrax Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Anthrax Therapeutics by Drug Class - Antibiotics, Immunoglobulins and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Anthrax Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Immunoglobulins and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Anthrax Therapeutics by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Anthrax Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION